Kristina willgård

Medicinteknikbolaget Add­­Life, ett koncern tillsammans med drygt 70 bolag, existerar en från Stockholmsbörsens stora pandemivinnare. VD Kristina Willgård kunde beneath första kvartalet i tid presentera enstaka organisk tillväxt på ovan 50% samt tredubblad vinst.

AddLife har gynnats av bland annat ökad omsättning inom koncernens diag­no­­stikbolag kopplat mot coronatester, enstaka kraftigt förhöjd efter­frågan vid skyddsutrustning samt, i forskningsbolagen, en upphöjd aktivitet kring virusforskning. dock pandemin existerar i sig inte läka förklaringen, säger VD Kristina Wilgård.

”Det existerar vår traditioner och decentraliserade verksamhet såsom är orsaken till vår framgång”, redogör hon.

Hur bör man titta på AddLife, är detta ett sammansatt av enstaka samling små­företag? 

”Jag ser ej AddLife såsom ett konglo­merat. Vi äger en mängd dotterbolag tillsammans olika erbjudanden, men en otroligt starkt gemensamt DNA som fullfölja att oss kombinerar småskalighetens fördelar tillsammans storbolagets kraft och tillgångar. Vi bygger inte den stora pyra­miden utan äger en platt organisation. då det går bra till oss existerar det till att våra bolag var ute fattar rätt beslut och fullfölja rätt saker. Vi vid huvudkontoret stöttar våra dotterbolag med affärsutveck

Kristina Willgård &#; CEO, AddLife, Sweden

AddLife is a Swedish company that acquires and streamlines profitable market-leading niche companies in the field of life science. CEO Kristina Willgård examines the company’s international expansion strategy and the goal of doubling in size in five years, highlights her personal commitment to sustainability, and the challenges facing the laboratory and medical technology industries.

 

Can you introduce AddLife and the scope of its business?

AddLife is a value-adding company primarily active in the Nordic region, but also in Central and Eastern Europe. We focus on Medtech and Labtech within life science. At our core, we are a distributor because we sell other suppliers&#; products in the markets where we are present. We also sell our own products in selected niches, primarily within medtech and especially the homecare segment. The Nordics and many other countries where we are present have high entry barriers. It is costly to enter because of cultural differences, language differences, geography and almost everything we sell is through public procurement. Even for excellent niche manufacturers or suppliers, it is extremely d

• C-RAD's nomination committee proposes that Kristina Willgård be elected as the new chairman of the board
• C-RAD's election committee further proposes that Susanne Ekblom and Peter Simonsbacka are elected as new board members.
• The chairman Lars Nyberg has informed the nomination committee that he will not stand for re-election to the board. Furthermore, Per-Arne Blomquist, Kicki Wallje-Lund and Åsa Hedin have informed the nomination committee that they do not stand for re-election to the board.

The nomination committee proposes that the following persons be elected as board members:

• Kristina Willgård, new election, chairman
• Jenny Rosberg, re-election
• David Sjöström, re-election
• Susanne Ekblom, new election
• Peter Simonsbacka, new election

Kristina Willgård, new election chairman, has long-term international experience from leading positions within Swedish trade and industry. Most recently as CEO of the Large Cap and Med Tech company Add Life (NASDAQ: ALIF) and she is currently a board member in i.e., Addnode Group, Ernström Group, Mölnlycke.

Susanne Ekblom (new election): has long-term business experience as CFO of Investor AB, CFO Dynamite within Scania